Cargando…

Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience

Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions...

Descripción completa

Detalles Bibliográficos
Autores principales: Fattizzo, Bruno, Levati, Giorgia Virginia, Giannotta, Juri Alessandro, Cassanello, Giulio, Cro, Lilla Marcella, Zaninoni, Anna, Barbieri, Marzia, Croci, Giorgio Alberto, Revelli, Nicoletta, Barcellini, Wilma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980524/
https://www.ncbi.nlm.nih.gov/pubmed/35392224
http://dx.doi.org/10.3389/fonc.2022.795955
_version_ 1784681413805604864
author Fattizzo, Bruno
Levati, Giorgia Virginia
Giannotta, Juri Alessandro
Cassanello, Giulio
Cro, Lilla Marcella
Zaninoni, Anna
Barbieri, Marzia
Croci, Giorgio Alberto
Revelli, Nicoletta
Barcellini, Wilma
author_facet Fattizzo, Bruno
Levati, Giorgia Virginia
Giannotta, Juri Alessandro
Cassanello, Giulio
Cro, Lilla Marcella
Zaninoni, Anna
Barbieri, Marzia
Croci, Giorgio Alberto
Revelli, Nicoletta
Barcellini, Wilma
author_sort Fattizzo, Bruno
collection PubMed
description Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions and of autoimmune phenomena to pathogenesis and clinical course, including leukemic evolution, is a field of open investigation. We analyzed data from a cohort of 226 patients with LR-MDS followed at our center in the last 20 years, focusing on morphological, immunological (antiplatelets and anti-erythrocyte autoantibodies, anti-erythroblast antibodies), and molecular features. Hypoplastic bone marrow was found in 7% of the cases correlating with younger age, deeper cytopenia, lower dysplasia, and worse response to ESAs. A marker of autoimmunity was observed in 46% of the tested cases, who were younger, were less frequent dysplastic changes, and responded better to ESAs and steroids. Finally, 68% of the tested cases displayed at least one somatic mutation, most commonly SF3B1, TET2, ASXL1, and SRSF2, associated with older age, presence of neutropenia, and lower response to ESAs. Leukemic evolution (2.2%) was associated with presence of somatic mutations, and survival was favorably related to response to ESAs and transfusion independence. Overall, granular evaluation and re-evaluation are pivotal in LR-MDS patients to optimize clinical management.
format Online
Article
Text
id pubmed-8980524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89805242022-04-06 Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience Fattizzo, Bruno Levati, Giorgia Virginia Giannotta, Juri Alessandro Cassanello, Giulio Cro, Lilla Marcella Zaninoni, Anna Barbieri, Marzia Croci, Giorgio Alberto Revelli, Nicoletta Barcellini, Wilma Front Oncol Oncology Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions and of autoimmune phenomena to pathogenesis and clinical course, including leukemic evolution, is a field of open investigation. We analyzed data from a cohort of 226 patients with LR-MDS followed at our center in the last 20 years, focusing on morphological, immunological (antiplatelets and anti-erythrocyte autoantibodies, anti-erythroblast antibodies), and molecular features. Hypoplastic bone marrow was found in 7% of the cases correlating with younger age, deeper cytopenia, lower dysplasia, and worse response to ESAs. A marker of autoimmunity was observed in 46% of the tested cases, who were younger, were less frequent dysplastic changes, and responded better to ESAs and steroids. Finally, 68% of the tested cases displayed at least one somatic mutation, most commonly SF3B1, TET2, ASXL1, and SRSF2, associated with older age, presence of neutropenia, and lower response to ESAs. Leukemic evolution (2.2%) was associated with presence of somatic mutations, and survival was favorably related to response to ESAs and transfusion independence. Overall, granular evaluation and re-evaluation are pivotal in LR-MDS patients to optimize clinical management. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980524/ /pubmed/35392224 http://dx.doi.org/10.3389/fonc.2022.795955 Text en Copyright © 2022 Fattizzo, Levati, Giannotta, Cassanello, Cro, Zaninoni, Barbieri, Croci, Revelli and Barcellini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Fattizzo, Bruno
Levati, Giorgia Virginia
Giannotta, Juri Alessandro
Cassanello, Giulio
Cro, Lilla Marcella
Zaninoni, Anna
Barbieri, Marzia
Croci, Giorgio Alberto
Revelli, Nicoletta
Barcellini, Wilma
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title_full Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title_fullStr Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title_full_unstemmed Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title_short Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
title_sort low-risk myelodysplastic syndrome revisited: morphological, autoimmune, and molecular features as predictors of outcome in a single center experience
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980524/
https://www.ncbi.nlm.nih.gov/pubmed/35392224
http://dx.doi.org/10.3389/fonc.2022.795955
work_keys_str_mv AT fattizzobruno lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT levatigiorgiavirginia lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT giannottajurialessandro lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT cassanellogiulio lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT crolillamarcella lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT zaninonianna lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT barbierimarzia lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT crocigiorgioalberto lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT revellinicoletta lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience
AT barcelliniwilma lowriskmyelodysplasticsyndromerevisitedmorphologicalautoimmuneandmolecularfeaturesaspredictorsofoutcomeinasinglecenterexperience